All In Biotech

Drug Trial Radar · NCT05332496

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

Efficacy and Safety of Transarterial Chemoembolization in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies(VEGF-TKI/Bevacizumab) for Intermediate Stage HCC

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

941

Actual

Start

Dec 28, 2022

Primary completion

Jul 30, 2023

Study completion Sep 14, 2025

Sponsor

Lead sponsor
Zhongda HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 18, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma

Interventions

  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumabDrug

    PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.

  • TACEProcedure

    TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival(PFS) per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)Time frame: up to approximately 2 years
  2. Overall Survival(OS)Time frame: up to approximately 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Gao-Jun Teng

    Nanjing, China

  • Zheng-Gang Ren

    Nanjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.